$RVNC
Revance Therapeutics, Inc.

2021 Q4 Form 10-Q Financial Statement

#000147929021000165 Filed on November 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $25.95M $19.75M $3.835M
YoY Change 133.15% 414.86% 8236.96%
Cost Of Revenue $7.881M $5.886M $1.090M
YoY Change 115.33% 440.0%
Gross Profit $18.07M $13.86M $2.750M
YoY Change 141.89% 403.96%
Gross Profit Margin 69.63% 70.19% 71.71%
Selling, General & Admin $44.56M $52.78M $48.18M
YoY Change -14.11% 9.54% 187.85%
% of Gross Profit 246.62% 380.85% 1752.11%
Research & Development $29.47M $30.10M $29.13M
YoY Change 0.78% 3.31% 12.7%
% of Gross Profit 163.09% 217.15% 1059.27%
Depreciation & Amortization $5.419M $5.150M $3.780M
YoY Change 25.44% 36.24% 417.81%
% of Gross Profit 29.99% 37.16% 137.45%
Operating Expenses $79.67M $82.88M $77.31M
YoY Change -6.75% 7.2% 81.55%
Operating Profit -$61.60M -$72.72M -$77.13M
YoY Change -20.99% -5.71% 81.31%
Interest Expense -$1.343M $1.571M $4.334M
YoY Change -53.21% -63.75%
% of Operating Profit
Other Income/Expense, Net -$151.0K -$146.0K -$146.0K
YoY Change -20.53% 0.0% 12.31%
Pretax Income -$63.10M -$74.38M -$81.26M
YoY Change -22.13% -8.47% 96.23%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$63.10M -$74.40M -$81.26M
YoY Change -19.43% -8.44% 96.23%
Net Earnings / Revenue -243.15% -376.8% -2118.83%
Basic Earnings Per Share -$1.10 -$1.34
Diluted Earnings Per Share -$926.0K -$1.10 -$1.34
COMMON SHARES
Basic Shares Outstanding 71.79M shares 67.78M shares 60.53M shares
Diluted Shares Outstanding 67.78M shares 60.53M shares

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $225.1M $273.7M $435.8M
YoY Change -48.44% -37.2% 108.52%
Cash & Equivalents $110.6M $127.2M $339.4M
Short-Term Investments $114.4M $146.5M $96.40M
Other Short-Term Assets $7.544M $8.352M $7.700M
YoY Change 30.07% 8.47% 18.46%
Inventory $10.20M $10.20M $4.000M
Prepaid Expenses
Receivables $3.348M $1.658M $2.585M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $246.1M $293.9M $450.1M
YoY Change -45.31% -34.71% 104.07%
LONG-TERM ASSETS
Property, Plant & Equipment $24.66M $22.03M $14.84M
YoY Change 40.93% 48.41% -0.5%
Goodwill $147.0M $147.0M $144.5M
YoY Change 0.0% 1.7%
Intangibles $55.33M $74.85M
YoY Change -22.44%
Long-Term Investments
YoY Change
Other Assets $8.701M $8.871M $1.154M
YoY Change 552.25% 668.72% -54.19%
Total Long-Term Assets $285.0M $287.9M $262.0M
YoY Change 5.49% 9.89% 479.18%
TOTAL ASSETS
Total Short-Term Assets $246.1M $293.9M $450.1M
Total Long-Term Assets $285.0M $287.9M $262.0M
Total Assets $531.2M $581.8M $712.1M
YoY Change -26.25% -18.3% 167.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.60M $8.038M $7.860M
YoY Change -16.23% 2.26% 13.88%
Accrued Expenses $39.56M $38.89M $37.66M
YoY Change 20.1% 3.26% 101.45%
Deferred Revenue $9.362M $10.94M $10.93M
YoY Change 19.25% 0.09% 108.57%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.29M $65.87M $63.65M
YoY Change 10.37% 3.49% 86.37%
LONG-TERM LIABILITIES
Long-Term Debt $280.6M $280.3M $177.4M
YoY Change 55.48% 58.02%
Other Long-Term Liabilities $1.485M $1.250M $98.30M
YoY Change -98.73% 22.26%
Total Long-Term Liabilities $1.485M $1.250M $275.7M
YoY Change -99.55% 242.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.29M $65.87M $63.65M
Total Long-Term Liabilities $1.485M $1.250M $275.7M
Total Liabilities $462.7M $461.7M $339.3M
YoY Change 33.75% 36.07% 196.25%
SHAREHOLDERS EQUITY
Retained Earnings -$1.398B -$1.300B -$1.050B
YoY Change 24.12% 23.81% 31.43%
Common Stock $1.466B $1.455B $1.421B
YoY Change -2.28% 2.41% 49.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.47M $120.2M $372.9M
YoY Change
Total Liabilities & Shareholders Equity $531.2M $581.8M $712.1M
YoY Change -26.25% -18.3% 167.91%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$63.10M -$74.40M -$81.26M
YoY Change -19.43% -8.44% 96.23%
Depreciation, Depletion And Amortization $5.419M $5.150M $3.780M
YoY Change 25.44% 36.24% 417.81%
Cash From Operating Activities -$44.61M -$53.17M -$55.69M
YoY Change -28.4% -4.53% 74.3%
INVESTING ACTIVITIES
Capital Expenditures -$4.357M -$1.002M -$780.0K
YoY Change 97.15% 28.46% -47.3%
Acquisitions
YoY Change
Other Investing Activities $32.00M $17.81M $33.27M
YoY Change -593.8% -46.47% 1286.25%
Cash From Investing Activities $27.64M $16.81M $32.49M
YoY Change -418.08% -48.27% 3431.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 405.0K -2.492M -690.0K
YoY Change -99.4% 261.16% 762.5%
NET CHANGE
Cash From Operating Activities -44.61M -53.17M -55.69M
Cash From Investing Activities 27.64M 16.81M 32.49M
Cash From Financing Activities 405.0K -2.492M -690.0K
Net Change In Cash -16.57M -38.85M -23.89M
YoY Change 350.14% 62.63% -23.21%
FREE CASH FLOW
Cash From Operating Activities -$44.61M -$53.17M -$55.69M
Capital Expenditures -$4.357M -$1.002M -$780.0K
Free Cash Flow -$40.25M -$52.16M -$54.91M
YoY Change -33.02% -5.0% 80.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001479290
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2020 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36297
dei Entity Registrant Name
EntityRegistrantName
Revance Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0551645
dei Entity Address Address Line1
EntityAddressAddressLine1
1222 Demonbreun Street, Suite 2000
dei Entity Address City Or Town
EntityAddressCityOrTown
Nashville
dei Entity Address State Or Province
EntityAddressStateOrProvince
TN
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
37203
dei City Area Code
CityAreaCode
615
dei Local Phone Number
LocalPhoneNumber
724-7755
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
RVNC
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71794852 shares
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
127177000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
333558000 USD
CY2021Q3 us-gaap Short Term Investments
ShortTermInvestments
146504000 USD
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
102947000 USD
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1658000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1829000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
10192000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
5876000 USD
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8352000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5793000 USD
CY2021Q3 us-gaap Assets Current
AssetsCurrent
293883000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
450003000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22029000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17499000 USD
CY2021Q3 us-gaap Goodwill
Goodwill
146964000 USD
CY2020Q4 us-gaap Goodwill
Goodwill
146964000 USD
CY2021Q3 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
59491000 USD
CY2020Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
71343000 USD
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45533000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
29632000 USD
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5057000 USD
CY2020Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3445000 USD
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8871000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1334000 USD
CY2021Q3 us-gaap Assets
Assets
581828000 USD
CY2020Q4 us-gaap Assets
Assets
720220000 USD
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8038000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
12657000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38887000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32938000 USD
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10941000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
7851000 USD
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4829000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4437000 USD
CY2021Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3179000 USD
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3081000 USD
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
65874000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
60964000 USD
CY2021Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
280319000 USD
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
180526000 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73757000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77294000 USD
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40466000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
27146000 USD
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1250000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2021Q3 us-gaap Liabilities
Liabilities
461666000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
345930000 USD
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
190000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
95000000 shares
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71838777 shares
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71838777 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
69178666 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
69178666 shares
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
72000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
69000 USD
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1454947000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1500514000 USD
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1334854000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1126293000 USD
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
120162000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
374290000 USD
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
581828000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
720220000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19745000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3835000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51848000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4192000 USD
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
52782000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48183000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152385000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
99013000 USD
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30095000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29130000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86787000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96027000 USD
CY2021Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
3705000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
2565000 USD
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
10219000 USD
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
3239000 USD
CY2021Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
92468000 USD
CY2020Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
80963000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
264920000 USD
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
199385000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-72723000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77128000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-213072000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-195193000 USD
CY2021Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
84000 USD
CY2020Q3 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
413000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
266000 USD
us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
2868000 USD
CY2021Q3 us-gaap Interest Expense
InterestExpense
1571000 USD
CY2020Q3 us-gaap Interest Expense
InterestExpense
4334000 USD
us-gaap Interest Expense
InterestExpense
4700000 USD
us-gaap Interest Expense
InterestExpense
10738000 USD
CY2021Q3 rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-20000 USD
CY2020Q3 rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-62000 USD
rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-98000 USD
rvnc Gain Losson Derivative Instruments Contract Net Pretax
GainLossonDerivativeInstrumentsContractNetPretax
-211000 USD
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-146000 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-146000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-608000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-406000 USD
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74376000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-81257000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-218212000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-203680000 USD
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
100000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-74376000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-81257000 USD
us-gaap Net Income Loss
NetIncomeLoss
-218212000 USD
us-gaap Net Income Loss
NetIncomeLoss
-203780000 USD
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-117000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000 USD
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-74377000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-81374000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-218215000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-203783000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-74376000 USD
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74376000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-81257000 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-81257000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-218212000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-218212000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-203780000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-203780000 USD
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.10
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.10
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.62
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67782033 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67782033 shares
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
60526740 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
60526740 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
67297954 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
67297954 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56233093 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56233093 shares
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
4493000 USD
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71838777 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
120162000 USD
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66587713 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
372853000 USD
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71838777 shares
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
120162000 USD
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
66587713 shares
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
372853000 USD
us-gaap Net Income Loss
NetIncomeLoss
-218212000 USD
us-gaap Net Income Loss
NetIncomeLoss
-203780000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
32513000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
24574000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14434000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5931000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
935000 USD
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
7576000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
16000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1351000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-140000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-474000 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0 USD
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
11184000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-171000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2492000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4316000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3976000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5141000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1254000 USD
rvnc Increase Decreasein Operating Lease Rightof Use Assets
IncreaseDecreaseinOperatingLeaseRightofUseAssets
15901000 USD
rvnc Increase Decreasein Operating Lease Rightof Use Assets
IncreaseDecreaseinOperatingLeaseRightofUseAssets
-1085000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
7537000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-515000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-4578000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
147000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
5784000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
17142000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-447000 USD
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
29883000 USD
rvnc Increase Decreasein Operating Lease Liabilities
IncreaseDecreaseinOperatingLeaseLiabilities
13712000 USD
rvnc Increase Decreasein Operating Lease Liabilities
IncreaseDecreaseinOperatingLeaseLiabilities
-1846000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1250000 USD
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-176927000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-116188000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
178588000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
239821000 USD
rvnc Prepayments For A Finance Lease
PrepaymentsForAFinanceLease
7700000 USD
rvnc Prepayments For A Finance Lease
PrepaymentsForAFinanceLease
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6018000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1890000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
135000000 USD
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
246500000 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 USD
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
16969000 USD
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20822000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
818000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
118000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-57306000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21706000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15029000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5476000 USD
rvnc Taxes Paid Related To Net Settlement Of Restricted Stock Awards
TaxesPaidRelatedToNetSettlementOfRestrictedStockAwards
6944000 USD
rvnc Taxes Paid Related To Net Settlement Of Restricted Stock Awards
TaxesPaidRelatedToNetSettlementOfRestrictedStockAwards
6005000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
327000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
337000 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
287500000 USD
rvnc Proceeds From Issuance Of Follow On Offering Net Of Commissions And Discount
ProceedsFromIssuanceOfFollowOnOfferingNetOfCommissionsAndDiscount
0 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
188104000 USD
rvnc Proceeds From Issuance Of Follow On Offering Net Of Commissions And Discount
ProceedsFromIssuanceOfFollowOnOfferingNetOfCommissionsAndDiscount
15581000 USD
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
0 USD
us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28865000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
9190000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
29464000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
264160000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-204769000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
168794000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
337003000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
171890000 USD
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
132234000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
340684000 USD
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
1206000 USD
us-gaap Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
336000 USD
rvnc Internally Developed Software Capitalized From Stock Based Compensation
InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation
792000 USD
rvnc Internally Developed Software Capitalized From Stock Based Compensation
InternallyDevelopedSoftwareCapitalizedFromStockBasedCompensation
415000 USD
us-gaap Net Income Loss
NetIncomeLoss
-218200000 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
0 USD
us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
43400000 USD
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-74400000 USD
CY2021Q3 rvnc Working Capital Surplus
WorkingCapitalSurplus
228000000.0 USD
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1300000000 USD
CY2021Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
273700000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates &amp; Risks and Uncertainties</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Such estimates include, but are not limited to, the fair value of assets and liabilities assumed in business combinations, the incremental borrowing rate used to measure operating lease liabilities, the recoverability of goodwill and long-lived assets, useful lives associated with property and equipment and intangible assets, the period of benefit associated with deferred costs, revenue recognition (including the timing of satisfaction of performance obligations, estimating variable consideration, estimating stand-alone selling prices of promised goods and services, and allocation of transaction price to performance obligations), deferred revenue classification, accruals for clinical trial costs, valuation and assumptions underlying stock-based compensation and other equity instruments, the fair value of derivative liability, and income taxes.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full extent of the impact of the COVID-19 pandemic on the Company’s future operational and financial performance is currently uncertain. The ongoing COVID-19 pandemic has caused a global slowdown of economic activity which has negatively impacted consumer spending, including with respect to our current and potential customers, while also disrupting sales channels and marketing activities. The extent to which the COVID-19 pandemic will further directly or indirectly impact our business, results of operations, financial condition, and liquidity will depend on future developments that are highly uncertain, including variant strains of the virus and the degree of their vaccine resistance and as a result of new information that may emerge concerning COVID-19, the actions taken to contain or treat it, and the duration and intensity of the related effects. The FDA was previously unable to conduct the required inspection of our manufacturing facility in Northern California, due to the FDA’s travel restrictions associated with the COVID-19 pandemic. Although the FDA inspection process has taken place and we have responded to the FDA’s observations from the inspection, we cannot be certain of how long it will take to remediate deficiencies identified by the FDA during the inspection and respond to the FDA or how quickly or successfully the regulatory approval process will move following our remediation of the deficiencies and our response to the FDA or the future impact of the COVID-19 pandemic on the submissions related to DaxibotulinumtoxinA for Injection in indications outside of glabellar (frown) lines, the progress of clinical trials, supplies and sales of the RHA® Collection of dermal fillers, demand for our products and other aspects of our operations. </span></div>As of the date of issuance of these condensed consolidated financial statements, we are not aware of any specific event or circumstance that would require us to update our estimates, judgments or revise the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained, and are recognized in the condensed consolidated financial statements as soon as they become known. Actual results could differ from those estimates and any such differences may be material to our condensed consolidated financial statements.
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4192000 USD
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19745000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51848000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3835000 USD
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
73757000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77294000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
85145000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4034000 USD
rvnc Contract With Customer Liability Billings And Adjustments Net
ContractWithCustomerLiabilityBillingsAndAdjustmentsNet
1963000 USD
CY2021Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
83074000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
148000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
30000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
359000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net Noncurrent
ContractWithCustomerAssetNetNoncurrent
85000 USD
CY2021Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
507000 USD
CY2020Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
115000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
260774000 USD
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
3000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
260771000 USD
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
380576000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
380576000 USD
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
260771000 USD
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
380576000 USD
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0 USD
CY2021Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
78534000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19043000 USD
CY2021Q3 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
59491000 USD
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
78534000 USD
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
7191000 USD
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
71343000 USD
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
4165000 USD
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2565000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11852000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3239000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
4156000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
16625000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
16625000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
10837000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
5967000 USD
CY2021Q3 rvnc Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
5281000 USD
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
59491000 USD
CY2021Q3 us-gaap Inventory Net
InventoryNet
10200000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
5900000 USD
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
23478000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17374000 USD
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
7448000 USD
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
6683000 USD
CY2021Q3 rvnc Accrued Inventory Current
AccruedInventoryCurrent
2567000 USD
CY2020Q4 rvnc Accrued Inventory Current
AccruedInventoryCurrent
1796000 USD
CY2021Q3 rvnc Accruals Clinical Trials Current
AccrualsClinicalTrialsCurrent
2528000 USD
CY2020Q4 rvnc Accruals Clinical Trials Current
AccrualsClinicalTrialsCurrent
3726000 USD
CY2021Q3 us-gaap Interest Payable Current
InterestPayableCurrent
629000 USD
CY2020Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1887000 USD
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2237000 USD
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1472000 USD
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38887000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32938000 USD
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
44102000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36990000 USD
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22073000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19491000 USD
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
22029000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17499000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y7M6D
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
2224000 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1460000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
5802000 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
4310000 USD
CY2021Q3 us-gaap Variable Lease Cost
VariableLeaseCost
385000 USD
CY2020Q3 us-gaap Variable Lease Cost
VariableLeaseCost
282000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
1016000 USD
us-gaap Variable Lease Cost
VariableLeaseCost
631000 USD
CY2021Q3 us-gaap Lease Cost
LeaseCost
2609000 USD
CY2020Q3 us-gaap Lease Cost
LeaseCost
1742000 USD
us-gaap Lease Cost
LeaseCost
6818000 USD
us-gaap Lease Cost
LeaseCost
4941000 USD
CY2020Q1 rvnc Capped Calls Premium Percentage Over Sale Price
CappedCallsPremiumPercentageOverSalePrice
1
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2539000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8298000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
8468000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
8723000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8981000 USD
CY2021Q3 rvnc Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
26389000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
63398000 USD
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
18103000 USD
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
45295000 USD
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098
CY2020Q1 rvnc Capped Calls Number Of Shares Subject To Anti Dilution Adjustments
CappedCallsNumberOfSharesSubjectToAntiDilutionAdjustments
8900000 shares
CY2021Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
3000000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
30000000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
30000000 USD
CY2021Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
30000000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
7956000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
5071000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
18855000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
723000 USD
rvnc Purchase Obligation Term Of Written Notice
PurchaseObligationTermOfWrittenNotice
P18M
CY2021Q2 rvnc Collaborative Agreement Extended Contractual Period
CollaborativeAgreementExtendedContractualPeriod
1 option_to_extend_lease_term
CY2021Q3 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
20000000 USD
CY2021Q3 us-gaap Other Commitment Due In Second Year
OtherCommitmentDueInSecondYear
13000000 USD
CY2021Q3 us-gaap Other Commitment Due In Third Year
OtherCommitmentDueInThirdYear
18000000 USD
CY2021Q3 us-gaap Other Commitment Due In Fourth Year
OtherCommitmentDueInFourthYear
25000000 USD
CY2021Q3 rvnc Other Commitment To Be Paid After Year Four
OtherCommitmentToBePaidAfterYearFour
164000000 USD
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1258000 USD
CY2020Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1258000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3773000 USD
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3159000 USD
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
313000 USD
CY2020Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
96000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
935000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
230000 USD
CY2021Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2020Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
2976000 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
7346000 USD
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1571000 USD
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
4330000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
4708000 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
10735000 USD
CY2020Q1 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28900000 USD
CY2020Q1 rvnc Capped Calls Price Cap
CappedCallsPriceCap
48.88
rvnc Indemnification Liability Recordedduring Period
IndemnificationLiabilityRecordedduringPeriod
0 USD
CY2020Q1 us-gaap Payments For Derivative Instrument Financing Activities
PaymentsForDerivativeInstrumentFinancingActivities
28900000 USD
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
0 shares
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10538000 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10677000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
32513000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24574000 USD
CY2021Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
329600000 USD
CY2020Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
326200000 USD
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19745000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3835000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51848000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4192000 USD
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-72723000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-77128000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-213072000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-195193000 USD

Files In Submission

Name View Source Status
0001479290-21-000165-index-headers.html Edgar Link pending
0001479290-21-000165-index.html Edgar Link pending
0001479290-21-000165.txt Edgar Link pending
0001479290-21-000165-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvnc-20210930.htm Edgar Link pending
rvnc-20210930.xsd Edgar Link pending
rvnc-20210930_cal.xml Edgar Link unprocessable
rvnc-20210930_def.xml Edgar Link unprocessable
rvnc-20210930_htm.xml Edgar Link completed
rvnc-20210930_lab.xml Edgar Link unprocessable
rvnc-20210930_pre.xml Edgar Link unprocessable
rvncq321exhibit101.htm Edgar Link pending
rvncq321exhibit311.htm Edgar Link pending
rvncq321exhibit312.htm Edgar Link pending
rvncq321exhibit321.htm Edgar Link pending
rvncq321exhibit322.htm Edgar Link pending
Show.js Edgar Link pending